Toward Precision Medicine in the Cardiorenal Syndrome
Toward Precision Medicine in the Cardiorenal Syndrome
复制标题
DOI：
10.1053/j.ackd.2018.08.017
复制
发表时间：
2018-09-01
影响因子：
2.9
通讯作者：
Cruz, Dinna N.
中科院分区：
文献类型：
--
作者：
Wettersten, Nicholas;Maisel, Alan S.;Cruz, Dinna N.
尽管肿瘤学领域在个体化精准医疗方面取得了重大进展，但心脏病学和肾脏病学仍然经常使用“一刀切”的方法。这也适用于心肾相互作用和心肾综合征的交叉点。最近的研究表明，肾功能恶化（WRF）对急性心力衰竭的预后影响是可变的。因此，有必要区分 WRF 的影响，以更好地指导精准护理。这最好使用生物标志物来进行，生物标志物可以让临床医生实时评估发生 WRF 时的生理状态。本综述将总结当前的心脏和肾脏生物标志物及其在心肾综合征评估中的地位。尽管我们对这种综合征的认识取得了进展，但仍需要进一步研究，将精准医学纳入心肾综合征患者护理的常规临床实践中。 (C) 2018 年，国家肾脏基金会，Inc. 保留所有权利。
Although the field of oncology has made significant steps toward individualized precision medicine, cardiology and nephrology still often use a "one size fits all" approach. This applies to the intersection of the heart-kidney interaction and the cardiorenal syndrome as well. Recent studies have shown that the prognostic implications of worsening renal function (WRF) in acute heart failure are variable; thus, there is a need to differentiate the implications of WRF to better guide precise care. This may best be performed with biomarkers that can give the clinician a real-time evaluation of the physiologic state at the time of developing WRF. This review will summarize current cardiac and renal biomarkers and their status in the evaluation of cardiorenal syndrome. Although we have made progress in our understanding of this syndrome, further investigation is needed to bring precision medicine into routine clinical practice for the care of patients with cardiorenal syndrome. (C) 2018 by the National Kidney Foundation, Inc. All rights reserved.